Treatment-Related Interstitial Lung Disease

Through the lens of multidisciplinary management in breast cancer, experts share practical insight on the identification and management of interstitial lung disease.

EP. 1: Managing Breast Cancer: Who’s Involved in Multidisciplinary Care?

August 25th 2021

Experts reflect on the importance of multidisciplinary care and outline the many disciplines involved in diagnosing and treating breast cancer.

EP. 2: Managing Breast Cancer: Collaboration Throughout the Treatment Journey

August 25th 2021

Comprehensive details on how multidisciplinary care is applied during a patient’s treatment journey, with a focus on pulmonology and critical care.

EP. 3: Difference in Breast Cancer Outcomes With Multidisciplinary Care

September 1st 2021

Shared insight on how nuanced multidisciplinary care can positively impact outcomes when treating a patient with breast cancer.

EP. 4: Multidisciplinary Care in BC: How Best to Communicate Patient Information

September 1st 2021

Focusing on the value of electronic systems and tumor boards, experts detail how best to communicate across disciplines in the management of breast cancer.

EP. 5: Challenges in the Multidisciplinary Management of Breast Cancer

September 8th 2021

Key opinion leaders highlight the challenges inherent in using multidisciplinary care to manage breast cancer, particularly when a patient is seen at multiple institutions.

EP. 6: Multidisciplinary Care for a Patient With Metastatic HER2+ Breast Cancer

September 8th 2021

An overview of optimal multidisciplinary care for a patient who presents with HER2+ metastatic breast cancer.

EP. 7: Breast Cancer Management: Monitoring Patients for ILD

September 15th 2021

In light of breast cancer therapies with the potential to cause interstitial lung disease, experts consider important patient risk factors and best monitoring practices.

EP. 8: Optimal Management of ILD in Patients With Breast Cancer

September 15th 2021

Shared insight on the optimal management of patients who develop interstitial lung disease while receiving therapy for breast cancer.